Stockreport

Medicenna Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program Patent covers the use of IL-2 Superkines such as MDNA11 to treat a wide ...

Medicenna Therapeutics Corp. - Common Shares  (MDNA) 
PDF TORONTO and HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-onc [Read more]